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Introduction: Immune checkpoint inhibitors have considerably changed the landscape in oncology. 
However apart world-acclaimed success stories limited to melanoma and lung cancer, many solid 
tumors failed to respond to immune checkpoint inhibitors, due to limited immunogenicity, 
unfavorable tumor micro-environment (TME), lack of infiltrating T lymphocytes or increase in Tregs.  
Areas Covered:  Combinatorial strategies is foreseen as the future of immunotherapy, and using 
cytotoxics or modulating agents is expected to boost the efficacy of immune checkpoint inhibitors. In 
this respect, nanoparticles displaying unique pharmacokinetic features such as tumor targeting 
properties, optimal payload delivery and long-lasting interferences with TME, are promising 
candidates for such combinations. This review covers the basis, expectancies, limits and pitfalls of 
future combination between nanoparticles and immune check point inhibitors. 
Expert Opinion: Nanoparticles allow optimal delivery of variety of payloads in tumors while sparing 
healthy tissue, thus triggering immunogenic cell death. Depleting tumor stroma could further help 
immune cells and monoclonal antibodies to better circulate in the TME, plus immune-modulating 
properties of the charged cytotoxics. Finally, nanoparticles themselves present immunogenicity and 
antigenicity likely to boost immune response at the tumor level.  
 




1. Current achievements and Limits of immunotherapies 
The use of immune checkpoint inhibitors has profoundly changed the evolution profile of cancer 
patients with advanced disease [1]. Antibodies targeting the T cell inhibitory receptors cytotoxic T-
lymphocyte antigen 4 (CTL A 4) and the programmed death receptor 1 (PD 1) (or its ligand PDL 1) are 
now clinically recognized with FDA approvals in melanoma, non-small-cell lung cancer (NSCLC), renal 
cell carcinoma and head and neck cancers to name but a few [2]. Checkpoint inhibitors have a 
different toxicity profile than chemotherapy with a lower incidence of pancytopenia or digestive 
toxicities which are the most frequent adverse events with chemotherapeutic agents. However initial 
over-optimism about checkpoint inhibitors has been tempered by the limited number of patients 
exhibiting spectacular response rates, or the issue of emerging specific toxicities [1]. Another 
limitation is the fact that baseline biomarker studies have shown that checkpoint blockade therapy is 
mainly active through reactivation of antigen specific T cells present within tumor micro-
environment (TME) [2]. It is a matter of fact that the majority of solid tumors do not exhibit a 
productive T cell infiltrate and can thus be considered as non-T cell-inflamed [2]. Thus turning cold 
tumors into hot tumors is currently one of the major goals to improve treatment of solid tumors with 
checkpoint inhibitors. 
2. Turning cold tumors into hot tumors: an ongoing challenge 
To achieve transforming cold tumors into hot ones, the wide range of possible combinations 
between immunotherapeutic agents and other drugs has to be appraised. A recent review by Lafolla 
and coworkers [3] covered a total of 410 combination trials involving two or more than two immune-
oncology drugs, mostly in skin and genitourinary malignancies. Gene expression data from TCGA 
were investigated and put into evidence 178 targets in 9089 tumors from 19 cancer-types. This 
allowed several promising new drug combinations to be identified. Above all, the impact of a 
combination between checkpoint inhibitors with cytotoxics or targeted agents to reshape tumor 
milieu in order to get immune infiltrate compatible with an expected activity of the checkpoint 
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inhibitors is getting more and more attention [4]. The main contributor for a replenishment of 
cytotoxic T cells is the tumoral neo-epitope production [5]. This neo-epitope production can be 
stimulated in different way, such as co-administration of agents, the most efficient ones being 
standard cytotoxic drugs (5). Modulation of the immune response through checkpoint inhibition may 
be increased by cytotoxic chemotherapy not only through the potential for neo-antigen cross-
presentation but also by inhibiting the ratio of cytotoxic lymphocytes to T regulatory (Tregs) 
lymphocytes [6] or blocking the STAT6 pathway to upregulate dendritic-cell activity [7].  
3. Nanoparticles at a glance 
Nanoparticles are small (i.e., <200 nm) entities designed to cargo anticancer agents throughout the 
body to the tumor site. Beyond canonical liposomes, a wide range of supports and scaffolds have 
been made available now, ranging from  dendrimers, squalene derivatives, nanospheres, to inorganic 
carriers such as silica beads or gold nanoparticles [8]. Despite their heterogeneity (Figure 1), all these 
nanoparticles share common features, such as ability to passively target tumor tissue and to 
accumulate preferentially in the tumor micro-environment, through the Enhanced Permeation and 
Retention effect (EPR effect). Indeed, provided that their size is below 200 nm, nanoparticles will 
pass through gaps and loose tight junctions of the tumor neovessels, thus enabling a preferential 
extravasation in tumor neighborhood.  In addition, the latest generation of nanoparticles such as 
immunoliposomes or conjugated nanoparticles can further target actively tumor antigens or tumor 
micro-environment [9]. Overall, nanomedicines in oncology all aim at improving the efficacy/toxicity 
balance of cytotoxics through an optimized biodistribution profile sparing healthy tissues and 
targeting tumor cells (Figure 2) [10]. In addition to carrying drugs, nanoparticles can be further used 
in theranostic applications such as iron-oxyde constructs [11], or radiosensitizing agents [12], 
highlighting how the carrier itself could have therapeutic applications.  This per se efficacy could 
come from intrinsic properties of inorganic particles, such as antibody-dependent cell cytotoxicity 
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(ADCC) – even when < 200 nm, nanoparticles are large enough to trigger immunogenic response, 
especially when they are composed of inorganic materials [13]. 
 
4. How nanoparticles could help to preserve patient’s innate immunity while delivering 
cytotoxics. 
Cancer patients are generally heavily treated by a wide variety of drugs but standard cytotoxics 
remain the backbone of most regimens in solid tumors. The canonical and common drug-related 
toxicity of most cytotoxics is pancytopenia, leading to sepsis and sometimes lethal outcome in the 
most dramatic cases [14]. This side-effect is the direct consequence of the non-specific mechanism of 
action of the vast majority of cytotoxics, which have all been selected to interfere with rapidly-
dividing cells such as cancer cells. Because hematopoietic progenitors are also rapidly-dividing cells, 
they are doomed to be affected by most chemotherapy regimen, regardless of the pharmacological 
class (e.g., antimicrotubules, antimetabolites, or alkylating agents to name but a few). In the light of 
the critical importance of innate immunity against cancer, one can assume that affecting 
lymphocytes count or other cells implicated in the immune response will have deleterious effects on 
the clinical outcome first, and will impair the efficacy of any immunotherapy-based strategy next, 
thus triggering innate resistance. For instance, several studies have suggested that elevated 
neutrophil-to-lymphocyte ratios (i.e., NLR >5) or diminished absolute lymphocyte count are 
associated with poor clinical outcome in patients treated with immune check point inhibitors [15,16]. 
It has already been shown that prior treatment with cytotoxics and history of drug-related 
lymphopenia are associated with poor prognosis of various cancer types [17,18]  and considered now 
as a possible unfavorable factor in patients treated with immune check point inhibitors [19]. This 
hypothesis is however controversial and other studies have failed to confirm this relationship, at 
least during phase-I studies [20]. Indeed, transient lymphopenia can be an opportunity for reshaping 
the repertoire of immune cells [21], thus explaining why an in-depth understanding of the duration 
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and level of chemo-induced lymphopenia plus full characterization of the kinetics of T-cells recovery 
is critical to better picture the impact of lymphopenia on homeostatic proliferation and efficacy of 
immune check-point inhibitors. As seen before, one of the most remarkable achievement of 
nanoparticles is their ability to target tumor tissue, thus sparing, at least partly, healthy cells and 
reducing thereby canonical cytotoxics-related side effects such as hematological toxicities. Several 
experimental data showed how the biodistribution of anticancer agents shifts from totally non-
specific when used as free drugs to a more tumor-directed distribution when used as nanoparticles. 
For instance, tumor VS. healthy tissue comparative biodistribution studies showed that paclitaxel is 
more concentrated in tumors and less in liver, spleen or kidneys when administered as nab-
paclitaxel, a 120 nm conjugated form of paclitaxel linked to a bioengineered albumin that targets 
SPARC and other glycoproteins of the TME [22]. As a direct consequence of this increase in tumor-
targeting properties, several studies have shown how nanoparticles led to reducing side effects in 
patients scheduled for chemotherapy. Because one of the canonical treatment-related severe 
toxicity is pancytopenia, sparing hematopoietic progenitors could help to maintain patient’s innate 
immune system functional. For instance, liposomal doxorubicine or liposomal vincristine show both 
reduced toxicities as compared with free doxorubicine or free vincristine [23,24]. In a non-clinical 
study, it has been demonstrated that stealth liposomal 5-FU was less likely to trigger severe 
leucopenia than standard 5-FU [25]. Similarly, severe neutropenia appeared less in patients treated 
with nab-paclitaxel drug conjugate, as compared with standard paclitaxel [26], and model-informed 
studies have further confirmed how paclitaxel nanoparticles were less toxic against blood cells [27]. 
More recently, in the Napoli-1 trial, liposomal irinotecan associated with LV-5-FU led to 18% of 
severe hematological toxicities, a figure markedly lower than the incidence of this toxicity when 
standard irinotecan is associated with 5-FU, such as the FolFiri regimen [28]. Finally, by sparing 
hematologic progenitors, nanoparticles can be indirectly further helpful in patients scheduled for 
immunotherapy, by reducing the need to use antibiotics in patients. Indeed  reducing toxicities, 
especially the neutropenia-related infections, will lead to cutting broad-spectrum antibiotherapy, 
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whom administration has been repeatedly associated with reduced survival in immunotherapy-
treated patients [29], much probably because of the disruption of gut microbiome necessary to the 
immune surveillance, e.g. by enhancing the function of dendritic cells and elevating recruitment and 
function of T cells interacting with these later [30]. Overall, because they are better tolerated, using 
nanoparticles to deliver anticancer agents could be a promising strategy when a patient is scheduled 
next for immunotherapy because it is more protective towards patient’s immunity, both by reducing 
the incidence of hematological toxicities and by limiting antibiotics whom use has been proven to be 
deleterious on survival. 
5. How Nanoparticles could increase neo-antigens burden and modulate actors of immune 
response. 
Standard anticancer agents are expected to boost immunotherapy at least in two distinct ways: by 
triggering immunogenic cell death and by adding effects on cancer and normal host cells in the TME.  
5.1. Delivering immunogenic agents.  
Lack of suitable neo-antigens and disruption in antigen processing or presentation is usually 
associated with impaired immune response to cancer [31]. Consequently, promoting immunogenic 
cell death prior introducing immune check-point inhibitors should help improving efficacy, 
supporting the hypothesis that cytotoxics should be associated indeed with immunotherapy [32,33]. 
Immunogenic response induced by cytotoxics probably involves the purinergic receptor P2RX7 or the 
pattern recognition receptor toll-like receptor-4 (TLR-4) [34]. In addition, intrinsic tumor 
immunogenicity can be enhanced with cytotoxics by upregulating tumor antigens such as CEA or by 
increasing tumor antigen presentation and recruitment of antigen presenting cells (APCs), i.e. 
through the overexpression of MHC class-I molecules.  Using nanoparticles should further trigger 
immunogenic response, because they frequently exhibit higher cytotoxicity as compared with 
standard drugs. For instance, liposomal 5-FU shows greater antitumor properties, both in vitro and in 
vivo, as compared with free 5-FU. In particular, stealth liposomal 5-FU induces deeper TS inhibition in 
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colorectal cell lines, thus triggering Fas-mediated apoptosis because of the thymineless stress in 
cancer cells [35]. In a quite similar way, liposomal gemcitabine proved to perform better than 
standard gemcitabine in pancreatic cancer models [36], and nab-paclitaxel exhibited higher 
antiproliferative efficacy than free paclitaxel in a variety of solid tumors [22]. The superior 
antiproliferative efficacy of nanoparticles over standard cytotoxics has been confirmed at bedside as 
well, since liposomal vincristine was found to be more effective than standard vincristine [24] 
whereas the combo daunorubicine + cytarabine given as a liposomal formulation improved response 
rates as compared with standard combination in patients with myelodysplastic syndromes [37]. In 
addition to the selective delivery of cytotoxics likely to trigger immunogenic cell death, nanoparticles 
can be further used to deliver antigens or adjuvants to specifically dendritic cells (DCs). For instance, 
lymph node-targeting nanoparticle-conjugate vaccines (i.e., TAA-NP and CpG-NP) proved to induce 
stronger cytotoxic CD8+ T-cell responses, higher antiproliferative  efficacy and extended survival  in 
mice bearing melanoma [38].  
 
5.2. Modulating TME Immune cells. 
In addition to promoting cancer immunogenicity by increasing neo-antigens burden, nanoparticles 
carrying cytotoxics or cytokines could modulate as well immune response through a variety of 
mechanisms, ranging from upregulating the expression of MHC Class I molecules to which the 
antigens bind, upregulating of co-stimulatory molecules and PD1/PDL1 expression, to 
downregulating co-inhibitory molecules such as PD-L1/B7-H1 or B7-H4, thus enhancing the strength 
of effector T cell activity. For instance, canonical 5-FU can abrogate Myeloid Derived Suppressive 
Cells (MDSCs) and Treg activity, while additionally it makes T cell-mediated lysis more effective 
through Fas-dependent mechanisms [39–41]. Cisplatin and cyclophosphamide both proved to 
decrease Tregs expression and to increase CD8+ T cell activity [42]. In addition to modulating T 
lymphocytes, chemotherapy, especially when administered with low dose such as following 
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metronomic regimen, can modulate as well DCs phenotype and function. For instance vinca-
alkaloids, taxanes and cyclophosphamide proved to enhance the function of DCs, much probably 
through an IL-12 dependent mechanism [43,44]. Much interestingly, the very distribution profile of 
nanoparticles, which are expected to nest in the TME and start releasing their payload regularly and 
over a long period of time, could meet this metronomic-like exposure required to enhance DC. One 
of the common features of all drug-carriers is indeed to stay longer in the tumor site, whereas free 
drugs enter massively before being rapidly cleared out of the tumor tissue. Consequently 
pharmacodynamic properties of standard cytotoxics are best described by the Hill equation, i.e. the 
higher the dose, the higher the effect on tumor cells or TME, with no lag compartment when 
modeling the effects. In contrast, the complex interplay between carrier’s PK, payload release, 
carrier’s interactions with TME, makes the PK/PD  profiles of nanoparticles more likely to ensure a 
sustained and constant release of cytotoxics at the tumor site [10]. In addition and because of the 
complete lack of specificity of anticancer agents, the high dose regimen required to trigger 
immunogenic cell death will have deleterious impact on bone marrow cells (see previous paragraph), 
with subsequent lack of clonal expansion of T cells.  This calls for using nanoparticles to redefine 
optimal dosing and scheduling of cytotoxics, so as to limit their hematological toxicities while 
preserving immunogenic cell death at the tumor level. In addition, drastic tumor debulking with 
cytotoxics leading to minimal residual disease may mitigate the negative impact of tumor burden on 
the efficacy of immune check point inhibitors. In this context, using nanoparticles once again could 
help to solve this once contradictory issue, because PK/PD relationships of nanoparticles allow 
sparing healthy cells while exerting maximal antiproliferative efficacy at the tumor level [10]. 
Although published data remain sparse, it has been recently confirmed that nanoparticles could 
achieve higher antiproliferative efficacy when combined to immune check point inhibitors because of 
their immunomodulating properties. For instance after having demonstrated how topoisomerase-I 
inhibitors such as irinotecan could enhance T-cell-mediated cytotoxicity of melanoma tumors in vitro, 
liposomal irinotecan was associated with anti-PDL1 in tumor-brearing-mice. Results confirmed 
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greater efficacy of this association, much probably because of the higher cytotoxic functionality 
observed with CD8+ T cells in the combination group [45].  
5.3. Triggering immunogenic response.   
Nanocarriers themselves can exert some kind of immunomodulation on their own, due to their 
physico-chemical composition. Despite being < 200 nm, nanoparticles remain foreign objects likely to 
be recognized by the MPS.  When circulating in the body, this could be an issue associated with lack 
of stability and different strategies can be undertaken to increase nanoparticle stealthness, such as 
surface pegylation [46]. However once the TME is reached, immunogenicity and antigenicity of 
nanoparticles could help to boost immune response against cancer [47]. Generating antibodies 
against nanoparticles can be obtained through a thymus-dependent pattern. Bioengineered 
nanoparticles will activate DC’s producing cytokines that activate T-helper cells. These T-helpers will 
recognize next antigens from APCs and finally prompt B cells to proliferate and to differentiate 
against the antigenic nanoparticles. In addition, B-cell activation can be achieved by repetitive 
elements in the antigen without T-cell involvement [48]. Of note, beyond inorganic scaffolds such as 
metal-based nanoparticles [49], it has been shown that antibodies can be raised even against 100% 
biocompatible lipid carriers such as liposomes [50,51]. Of note, even surface pegylation, a common 
strategy in nanomedicine to increase stealthness and mask nanoparticles from scavengers and 
phagocytic cells, can show some immunogenicity as anti-PEG IgM have been already described in 
non-clinical models [52]. Nanoparticles immunogenicity could be therefore mostly based upon 
antibody-dependent cell cytotoxicity (ADCC)-like mechanism, the antibodies being capable to 
recognize either surface groups or core components. Because in oncology nanoparticles are expected 
to preferentially accumulate and concentrate in tumors, this immunogenicity could contribute to 
attract in TME new actors of the immune response. However, to what ADCC could contribute to a 
better efficacy when using next immune check point inhibitors must be clearly investigated, as some 
nanoparticles showed inconsistent results. For instance, silicon nanoparticles encapsulated with 
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sorafenib and coated with anti-CD326 antibodies showed increased efficacy in various breast cancer 
models. However, concentration-dependent ADCC was evidenced in MCF7 cells, but not in the MDA-
MB231 model [53], whereas elsewhere a complete lack of ADCC mechanism was reported with gold 
nanoparticles [54]. Despite this discrepancy in ADCC properties, several strategies have been 
successfully tested to boost patient’s immunity. For instance, inorganic nanoparticles (i.e., polymeric 
or gold) with surface modifications were used to target Tumor Associated Macrophages (TAM) 
thanks to PEG-sheddable, mannose-modified constructs [55]. Elsewhere, artificial APCs for direct CTL 
activation were achieved using iron-oxide nanoparticles coated with dextran and quantum dots 
coated with avidin led to an increase in T-cells and successful tumor rejection in melanoma-bearing 
mice [56].   
 
6. Helping immune cell and therapeutic monoclonal antibodies to better trafficking into 
tumor micro-environment 
Tumor-associated immune factors and chemokines in TME are heterogeneous and play a critical role 
in determining clinical outcome in cancer patients treated with immune checkpoint inhibitors. As 
early of the early 2000’s it was found that TME was associated with higher turnover of T- 
lymphocytes, as compared with non-cancerous tissue, suggesting that targeting TME could be of 
importance in the era of immunotherapy because of its immunosuppressive properties [57]. By 
affecting TME cytotoxics may enhance the efficacy of tumor-educated lymphocytes. The higher the 
amount of cytotoxics in tumor surrounding, the more effective will be the action on tumor stroma, 
desmoplastic cells, fibroblasts and eventually tumor cells. However, it seems that the balance 
between direct cytotoxicity (and subsequent immunogenic cell death), depleting effect on TME, and 
immunomodulating properties of cytotoxics all depends on the dosing and the scheduling of the 
regimen, and should be finely tuned as it is probably drug-dependent. It has been demonstrated, 
long before immunotherapy was on the rise, that neo-adjuvant paclitaxel could ease new 
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intratumoral immune cell infiltrates with subsequent higher apoptotic response and clinical efficacy 
in breast cancer [58]. Much interestingly, paclitaxel can be delivered either as a cremophor 
formulated drug, or as a conjugated nanoparticle, nab-paclitaxel. Nab-paclitaxel proved to deplete 
tumor stroma, reducing density and disrupting tumor micro-environment, in addition to direct effect 
on tumor cells microtubules. Because one of the main causes for immune escape is unfavorable TME 
[59], such additional mechanism of action is likely to make hot an initially cold tumor, thus further 
easing the infiltration of dendritic cells and antigen-experienced T cells as compared with free 
paclitaxel. Indeed, tumor-specific CD8 T-cells subsequently differentiated into effector T-cells require 
trafficking to the TME prior to kill cancer cells expressing neoantigens. By depleting tumor stroma, 
nanoparticles could actually both enhance the infiltration in TME of T cells, but as well that of 
therapeutic monoclonal antibodies such as immune checkpoint inhibitors which are usually 
molecules too large to properly reach solid tumors because of high stroma density and binding-site 
barrier issues [60]. Although to date no experimental data are available to support this hypothesis 
because little is known on the tumor distribution of immune check-point inhibitors in vivo, one can 
speculate that depleting effect on TME by nanoparticles should additionally increase drug delivery of 
these large therapeutic antibodies next.  
 
7. Conclusion: How nanoparticles could be best combined with immunotherapy. 
Overall, nanoparticles can be used to boost immunotherapy in several ways. Optimizing delivery at 
the tumor site of a variety of payloads ranging from cytotoxics triggering immunogenic cell death, 
cancer vaccine or therapeutic RNAs is an appealing strategy. Interestingly, nanotechnologies offer 
today such a wide sort of scaffolds that there is no limit but the imagination of the researchers to 
achieve this goal (Figure 2).  For instance gold nanoparticles have been designed to deliver anti-VEGF 
siRNA both to TAMs and to lung cancer cells, achieving a synergistic efficacy in tumor-bearing mice 
[61]. Elsewhere, dendrimers loaded with paclitaxel conjugated with mAbK1 antibodies proved to be 
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effective in ovarian cancer mice models [62]. Nontoxic core-shell nanoparticles encapsulating 
photosensitizer pyrolipid proved to increase the efficacy of anti-PDL1 in metastatic breast cancer 
models, partly by increasing tumor mutational burden after photodynamic therapy [63]. In breast 
cancer model again, liposomal nanoparticle coated with tumor-targeting peptide and co-
encapsulating anti-PI3K drug plus a specific agonist of therapeutic T cells, proved to act synergistically 
when CAR-T cells were administered next. Increase of immune effector cells such as CD8+ 
lymphocytes and invariant natural killer cells were evidenced, and increase in efficacy was further 
confirmed in a mouse model of human glioblastoma [64]. Elsewhere nanogels carrying interleukin-15 
were successfully developed to boost mouse T cell and CAR-T cell therapy  in a melanoma model 
[65]. In addition to drug delivery properties or tumor micro-environment reshaping, nanoparticles 
can also exhibit directly some immunogenic properties. Size, composition, surface properties, electric 
charge, all probably matter and call for a comprehensive understanding of the immunogenicity and 
antigenicity of nanoparticles. For instance, cobalt oxide nanoparticles coated with PMIDA and 
conjugated to a lysate antigen triggered increase in IgG and CD4+ response in mice [66]. In breast 
cancer models, manganese dioxide liposomal nanoparticles combined with doxorubicin increased the 
infiltration of CD8+ T cells in TME, thus boosting antitumor efficacy as compared with free 
doxorubicine alone. Much interestingly, naïve tumor-bearing mice transplanted with splenocytes 
from mice previously treated by this combination were able to control tumor growth, whereas 
splenocytes from control mice or from doxorubicine-treated mice had no antiproliferative effect, 
thus highlighting how immunomodulating properties of nanoparticles were at the origin of the 
observed efficacy [67]. Although only experimental, all these studies pave the way for future 
combinations with immune check point inhibitors.  However, there are several pitfalls in developing 
combinatorial strategies between nanoparticles and immunotherapy.  First, the most immunogenic 
nanoparticles such as the ones based upon metal, silica nanosphere of other inorganic or polymeric 
components, have all unaddressed issues in terms of nanosafety, because little is known about their 
possible long-term effects once injected in the body [68]. In addition, being too immunogenic may 
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expose nanoparticles to early recognition by macrophages and scavenging cells before the 
nanoparticles even reach the tumor site. Second, apart long-studied liposomes, little is known about 
the exact pharmacokinetic profile of the most recent nanoparticles, because their unique features 
differ to that of standard drugs [10,46]. Extensive PK/PD modeling is therefore much awaited to 
better understand how and when nanoparticles should be best combined with immune check-point 
inhibitors.  For instance, increasing mutational burden and achieving drastic tumor debulking is more 
likely to be observed when high concentrations of cytotoxics reach tumor cells, whereas 
immumodulating properties on DCs, Tregs or effector T-cells have been conversely reported with 
metronomic regimen leading to sustained and continuous exposure to low levels of drugs [69]. The 
era of trial-and-error strategies, inherited from the 20th century medicine, is gone and with respect to 
the possible number of combinations made available now, strong pharmacometric support is 
mandatory to ensure successful development of immuno-nano-therapeutics. 
 
Expert Opinion: 
Beyond the initial frenzy sparked by the successful stories in melanoma and lung cancer, 
immunotherapy seems to have reached a glass-ceiling in oncology, at least as single-agents.  Poor 
trafficking of activated T lymphocytes to the tumors, massive recruitment of Tregs or MDSCs in the 
tumor micro-environment, low mutational burden, are the most frequent reasons explaining the 
innate resistance of most solid tumors towards immune checkpoint inhibitors.  Pre-treating patients 
with agents likely to boost immune response is therefore an appealing strategy to optimize the 
efficacy of immunotherapy.  Nanoparticles present a wide range of characteristics such as optimized 
drug delivery in the tumor surroundings and immunogenic properties that make them suitable 
candidates for combinatorial strategies with immune checkpoint inhibitors. In addition, nanoparticles 
can cargo a limitless number of payloads such as cytotoxics, cytokines, vaccines or nucleotides, all 
likely to modulate tumor immunity or to trigger immunogenic cell death. However, a current 
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bottleneck in the clinical development of nanoparticles remains scale-up issues and pitfalls when 
shifting from bench-size batches to clinical-size batches. Apart from liposomes and 
immunoliposomes for which proof-of-concepts of successful industrial production has already been 
made, the complexity to produce large and reproducible batches of sophisticated scaffolds has to be 
taken into account and could be a limitation to future bedside applications. Nanosafety issues and 
emerging tight regulations regarding manufacturing and handling of nanoparticles also has to be 
taken into account as a possible limitation, especially with inorganic materials [70]. In addition, there 
is another possible safety risk when administrating highly immunogenic nanoparticles in combination 
with immune check point inhibitors, because of a possible potentiation of immune-related adverse 
effects (IRAEs) reported with immunotherapy. In addition, immunogenic nanoparticles can also be 
recognized by scavenging cells or macrophages when trafficking in the blood, spleen or liver, thus 
having little chance to reach the tumor. Stealthness is a common strategy to limit spleen or liver 
uptake – however designing a nanoparticle smart enough to be stealth in healthy tissue to limit IRAEs 
while triggering immunogenicity only once malignant tissue are reached is particularly challenging.  
Finally, lessons have to be learned from previous recent failures when trying to combine empirically 
immune check-point inhibitors with other treatments such as metronomic chemotherapy, 
radiotherapy or anti-angiogenics. In-depth knowledge of nanoparticles PK/PD profiles, ideally using 
model-informed approaches, is urgently needed to better picture the optimal modality to combine 
nanoparticles with immunotherapy. The complexity in the multiple and possibly contradictory effects 
on immune cells, especially when using encapsulated cytotoxics, require finely tuned protocols in 
terms of dosing, sequencing and treatment duration. With respect to the number of treatment 
modalities and scheduling, extensive mathematical resources are required to help determining in 
silico the strategy that is the most efficient to yield synergistic effect between nanoparticles, immune 
check-point inhibitors, and possibly other drugs likely to boost efficacy such as anti-angiogenics. 
Should the optimal conditions be met, because nanoparticles are more protective towards 
hematopoietic progenitors and therefore less likely to trigger lymphopenia, not to mention stroma-
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targeting properties and boosting tumor immunogenicity, they could be of great value for awakening 





Article highlights  
• Immunotherapy is currently limited by cold tumors displaying unfavorable immunogenic 
profile because of low mutational burden, harsh tumor micro-environment, plus possible 
deleterious impact of prior chemotherapy on patient’s innate immunity. 
• Combinatorial therapy is seen as the future of immunotherapy, and associated treatments 
are all expected to turn cold tumors into hot tumors, so as to boost the efficacy of immune 
check-point inhibitors.  
• Nanoparticles present promising features, making them particularly suitable candidates to be 
associated with immune check-point inhibitors.    
• Improved pharmacokinetics, immunogenic properties and ability to cargo a wide variety of 
anticancer drugs or immunomodulating agents provide nanoparticles with unique properties.  
• Determining the optimal modality of such combination is challenging because of the multiple 
and complex interplays between nanoparticles, patient’s immunity, tumor micro-
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Figure 1:  Different scaffolds and nanoparticles available to cargo payloads to the tumor site. NP: 
nanoparticle.  
 
Figure 2:  Schematic comparison of the biodistribution profiles of xenobiotics administered as free 
drugs (A) or as nanoparticles (B).  
 
Figure 3:  Representation of the possible multiple interplays between nanoparticles, cancer cells, and 
immune cells in the TME.  TAM: Tumor-Associated Macrophages.  MDSC: Myeloid Derived 
Suppressive Cells, APC: Antigen-Presenting Cells.  
 



